id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
work_7d44fueadjcdrmsiuphrqbc3ia	K Kelly	A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer	1999.0	7	.pdf	application/pdf	5175	500	66	The recommended doses for future clinical trials are 175 mg/m2 paclitaxel, i.v., over a 3-h period on day 1 with 80 mg/m2 cisplatin, i.v., on day 1 and 80 mg/m2 etoposide, i.v., on day 1 and Despite high response rates, relapse and progression develop in the majority of patients, and median survival 3 The abbreviations used are: SCLC, small cell lung cancer; PE, cisplatin and etoposide; PET, PE and paclitaxel; G-CSF, granulocyte-colony If a patient on G-CSF developed grade 4 leukopenia or neutropenia, prolonged neutropenia, or febrile neutropenia, a dose reduction of all three drugs was required, as on this regimen, with the majority of patients receiving paclitaxel doses of 105–130 mg/m2. neuropathy in five of seven patients receiving 200 mg/m2 paclitaxel over a 3-h period with 100 mg/m2 cisplatin in their dose Phase II study of paclitaxel in patients with extensive-stage small cell	./cache/work_7d44fueadjcdrmsiuphrqbc3ia.pdf	./txt/work_7d44fueadjcdrmsiuphrqbc3ia.txt